2.1888
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GDRX Giù?
Forum
Previsione
Precedente Chiudi:
$2.23
Aprire:
$2.23
Volume 24 ore:
1.15M
Relative Volume:
0.48
Capitalizzazione di mercato:
$741.66M
Reddito:
$775.09M
Utile/perdita netta:
$-58.68M
Rapporto P/E:
-16.51
EPS:
-0.1326
Flusso di cassa netto:
$64.06M
1 W Prestazione:
-4.37%
1M Prestazione:
-23.96%
6M Prestazione:
-37.43%
1 anno Prestazione:
-54.66%
Goodrx Holdings Inc Stock (GDRX) Company Profile
Nome
Goodrx Holdings Inc
Settore
Industria
Telefono
(855) 268-2822
Indirizzo
2701 OLYMPIC BOULEVARD, SANTA MONICA
Compare GDRX vs VEEV, TEM, BTSG, HQY, DOCS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
GDRX
Goodrx Holdings Inc
|
2.185 | 756.94M | 775.09M | -58.68M | 64.06M | -0.1326 |
|
VEEV
Veeva Systems Inc
|
171.47 | 29.10B | 3.08B | 860.33M | 1.35B | 5.1463 |
|
TEM
Tempus Ai Inc
|
49.70 | 9.54B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
BTSG
Brightspring Health Services Inc
|
38.34 | 7.22B | 11.99B | 24.18M | 234.31M | 0.2956 |
|
HQY
Healthequity Inc
|
74.25 | 6.57B | 1.15B | 96.70M | -161.99M | 1.09 |
|
DOCS
Doximity Inc
|
24.59 | 4.80B | 550.17M | 201.35M | 232.07M | 1.00 |
Goodrx Holdings Inc Stock (GDRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-22 | Downgrade | Jefferies | Buy → Hold |
| 2025-12-09 | Iniziato | Barclays | Underweight |
| 2025-08-11 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2024-12-04 | Iniziato | Mizuho | Neutral |
| 2024-08-09 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-05-23 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-16 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2024-04-10 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-03-25 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-03-01 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-02-26 | Iniziato | Leerink Partners | Outperform |
| 2024-01-02 | Downgrade | BofA Securities | Buy → Underperform |
| 2023-08-10 | Aggiornamento | DA Davidson | Neutral → Buy |
| 2023-07-31 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2022-12-01 | Iniziato | Citigroup | Buy |
| 2022-11-04 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-09-16 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | Iniziato | Truist | Hold |
| 2022-08-12 | Iniziato | DA Davidson | Neutral |
| 2022-06-10 | Downgrade | Goldman | Buy → Neutral |
| 2022-06-06 | Ripresa | BofA Securities | Buy |
| 2022-06-01 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-05-10 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-05-10 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-05-10 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-05-10 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-04-11 | Iniziato | Wells Fargo | Equal Weight |
| 2022-04-07 | Iniziato | Guggenheim | Buy |
| 2022-04-01 | Ripresa | Credit Suisse | Neutral |
| 2022-03-15 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-03-01 | Reiterato | Barclays | Overweight |
| 2022-03-01 | Reiterato | BofA Securities | Neutral |
| 2022-03-01 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-03-01 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-03-01 | Reiterato | Evercore ISI | Outperform |
| 2022-03-01 | Reiterato | Goldman | Buy |
| 2022-03-01 | Reiterato | JP Morgan | Underweight |
| 2022-03-01 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-03-01 | Reiterato | SVB Leerink | Outperform |
| 2022-01-07 | Iniziato | Goldman | Buy |
| 2021-12-21 | Iniziato | Stephens | Overweight |
| 2021-12-02 | Iniziato | Jefferies | Buy |
| 2021-08-31 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2021-08-13 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2021-05-28 | Iniziato | Robert W. Baird | Neutral |
| 2021-04-06 | Ripresa | Evercore ISI | Outperform |
| 2021-01-25 | Iniziato | Guggenheim | Buy |
| 2020-11-19 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-10-19 | Iniziato | Barclays | Equal Weight |
| 2020-10-19 | Iniziato | BofA Securities | Neutral |
| 2020-10-19 | Iniziato | Citigroup | Buy |
| 2020-10-19 | Iniziato | Cowen | Outperform |
| 2020-10-19 | Iniziato | Credit Suisse | Outperform |
| 2020-10-19 | Iniziato | Deutsche Bank | Hold |
| 2020-10-19 | Iniziato | Goldman | Neutral |
| 2020-10-19 | Iniziato | JP Morgan | Neutral |
| 2020-10-19 | Iniziato | Morgan Stanley | Overweight |
| 2020-10-19 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-10-19 | Iniziato | SVB Leerink | Outperform |
| 2020-10-19 | Iniziato | UBS | Buy |
Mostra tutto
Goodrx Holdings Inc Borsa (GDRX) Ultime notizie
How Recent Analyst Shifts Are Rewriting The Story For GoodRx Holdings (GDRX) - Yahoo Finance
GoodRx (NASDAQ:GDRX) Trading Up 7.9%Should You Buy? - MarketBeat
GoodRx (NASDAQ:GDRX) Trading Down 6.4%Should You Sell? - MarketBeat
GoodRx (GDRX) Lifts Guidance as Pharma Partnerships Drive Double-Digit Growth - MSN
Is GoodRx (GDRX) Using ARAKODA Discounts To Quietly Redefine Its Preventive Care Strategy? - Yahoo Finance
GoodRx Holdings, Inc.'s (NASDAQ:GDRX) biggest owners are retail investors who got richer after stock soared 7.5% last week - simplywall.st
GoodRx (GDRX) Partners with Pfizer for Discounts on TrumpRx - GuruFocus
Headwinds in GoodRx’s (GDRX) Drug Prescription Business Draw Cautious View from Jefferies - Insider Monkey
GoodRx becomes pricing source for Pfizer and other drugmakers on TrumpRx - Seeking Alpha
11 Best Stocks Under $3 to Buy Right Now - Insider Monkey
Amazon Is Now Offering Novo Nordisk's Wegovy Pill in Its Pharmacy. Here's How That Could Affect Hims & Hers, WW International, and GoodRx Holdings. - Yahoo Finance
Amazon Is Now Offering Novo Nordisk's Wegovy Pill in Its Pharmacy. Here's How That Could Affect Hims & Hers, WW International, and GoodRx Holdings. - The Motley Fool
GoodRx powers pricing for leading Brand Medications on TrumpRX - marketscreener.com
Pfizer cuts prices up to 85% on 30+ drugs via TrumpRx and GoodRx - Stock Titan
GoodRx stock climbs amid TrumpRx launch speculation By Investing.com - Investing.com Canada
GoodRx (GDRX) to Offer Savings on Arakoda in New Partnership - GuruFocus
GoodRx system that saved Americans $100B earns key data safety seal - Stock Titan
Risk Report: Can GoodRx Holdings Inc expand its profit marginsQuarterly Profit Report & Accurate Buy Signal Alerts - baoquankhu1.vn
Published on: 2026-01-30 09:08:15 - baoquankhu1.vn
GoodRx Announces Date for Fourth Quarter and Full Year 2025 Earnings Release and Conference Call - Caledonian Record
GoodRx Holdings, Inc. (GDRX) Stock Analysis: Exploring An 80% Upside Potential - DirectorsTalk Interviews
Is GoodRx Holdings Inc. showing insider buyingWeekly Investment Summary & Long-Term Safe Investment Ideas - mfd.ru
GoodRx (NASDAQ:GDRX) Hits New 1-Year LowShould You Sell? - MarketBeat
Q3 Earnings Highlights: GoodRx (NASDAQ:GDRX) Vs The Rest Of The Healthcare Technology Stocks - Finviz
GoodRx Holdings, Inc. (NASDAQ:GDRX) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Rate Hike: How does GoodRx Holdings Inc perform in inflationary periodsPortfolio Value Report & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Demystifying GoodRx Holdings: Insights From 8 Analyst Reviews - Benzinga
Weekly Recap: What is HBANLs revenue forecastGlobal Markets & Daily Profit Focused Stock Screening - baoquankhu1.vn
Activity Recap: Can GoodRx Holdings Inc deliver consistent EPS growthJuly 2025 Snapshot & Fast Gain Stock Trading Tips - baoquankhu1.vn
GDRX: Jefferies Downgrades GoodRx Holdings with Significant PT R - GuruFocus
Leerink Partners Remains Bullish on GoodRx Holdings (GDRX) - MSN
Jefferies downgrades GoodRx stock to Hold on prescription segment challenges - Investing.com Nigeria
Jefferies Downgrades GoodRx Holdings Inc. (GDRX) to Hold - StreetInsider
GoodRx Users Denied Nod For $32M Deal In Data Sharing Row - Law360
Valuation Update: Whats the MACD signal for GoodRx Holdings Inc2025 Market Overview & Smart Swing Trading Alerts - baoquankhu1.vn
GoodRx’s $32 Million Info-Sharing Deal Fails to Get Court Nod - Bloomberg Law News
GoodRx Holdings, Inc.'s (NASDAQ:GDRX) last week's 6.9% decline must have disappointed individual investors who have a significant stake - Yahoo Finance
GoodRx Holdings, Inc. (NASDAQ:GDRX) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? - simplywall.st
GoodRx won't be participating with TrumpRx: report - MSN
GoodRx (NASDAQ:GDRX) Upgraded at Wall Street Zen - MarketBeat
Aug Swings: What is the next catalyst for GoodRx Holdings IncJuly 2025 Drop Watch & Daily Price Action Insights - baoquankhu1.vn
Recap Report: What is the next catalyst for GoodRx Holdings IncBreakout Watch & Community Consensus Trade Alerts - baoquankhu1.vn
GoodRx CEO on TrumpRx and Surescripts Partnership - marketscreener.com
Performance Recap: Will GoodRx Holdings Inc stock deliver shareholder valueJuly 2025 Update & Consistent Return Investment Signals - Bộ Nội Vụ
Drug price tool shows pharmacy costs upfront with GoodRx savings - Stock Titan
BofA maintains underperform rating on GoodRx (GDRX) while trimming PT to $2.60 - MSN
BofA Maintains Underperform Rating on GoodRx (GDRX) While Trimming PT to $2.60 - Finviz
Citigroup Maintains Buy Rating on GoodRx (GDRX) but Lowers Price Target | GDRX Stock News - GuruFocus
Citigroup Has Lowered Expectations for GoodRx (NASDAQ:GDRX) Stock Price - MarketBeat
GoodRx Holdings (FRA:8GH) 3-Year RORE % : 57.89% (As of Sep. 2025) - GuruFocus
GoodRx Holdings (FRA:8GH) Days Inventory : 0.00 (As of Sep. 2025) - GuruFocus
Goodrx Holdings Inc Azioni (GDRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):